Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | NYSE | Healthcare | Pharmaceuticals | $725.90B | 87.2x | 1.25 | $804.99 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.3% Upside | Upgrade to Pro+ | |
UnitedHealth | NYSE | Healthcare | Healthcare Providers & Services | $499.45B | 34.9x | -0.97 | $542.48 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.8% Upside | Upgrade to Pro+ | |
Novo Nordisk ADR | NYSE | Healthcare | Pharmaceuticals | $379.06B | 28.8x | 1.09 | $85.19 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.8% Upside | Upgrade to Pro+ | |
J&J | NYSE | Healthcare | Pharmaceuticals | $363.77B | 26x | -0.43 | $150.38 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.8% Upside | Upgrade to Pro+ | |
AbbVie | NYSE | Healthcare | Pharmaceuticals | $309.43B | 60.9x | -2.76 | $174.81 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.2% Upside | Upgrade to Pro+ | |
Roche Holding ADR | OTC Markets | Healthcare | Pharmaceuticals | $249.38B | 22.6x | -6.4 | $38.94 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.1% Upside | Upgrade to Pro+ | |
Roche Holding Participation | OTC Markets | Healthcare | Pharmaceuticals | $249.38B | 22.6x | -6.4 | $309.55 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck&Co | NYSE | Healthcare | Pharmaceuticals | $246.51B | 20.3x | 0.12 | $97.45 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.4% Upside | Upgrade to Pro+ | |
Thermo Fisher Scientific | NYSE | Healthcare | Healthcare Equipment & Supplies | $223.12B | 36.4x | 7.86 | $584.29 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.5% Upside | Upgrade to Pro+ | |
Abbott Labs | NYSE | Healthcare | Healthcare Equipment & Supplies | $220.74B | 16.6x | 0.12 | $127.39 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.1% Upside | Upgrade to Pro+ | |
AstraZeneca PLC | OTC Markets | Healthcare | Pharmaceuticals | $215.49B | 33.2x | 3.36 | $137.21 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca ADR | NASDAQ | Healthcare | Pharmaceuticals | $215.49B | 33.2x | 3.36 | $69.59 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.9% Upside | Upgrade to Pro+ | |
Intuitive Surgical | NASDAQ | Healthcare | Healthcare Equipment & Supplies | $204.50B | 88.3x | 3.24 | $574.14 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.1% Upside | Upgrade to Pro+ | |
Novartis | OTC Markets | Healthcare | Pharmaceuticals | $204.42B | 11.9x | 0.13 | $102.65 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis ADR | NYSE | Healthcare | Pharmaceuticals | $204.42B | 11.9x | 0.13 | $101.84 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12% Upside | Upgrade to Pro+ | |
Danaher | NYSE | Healthcare | Healthcare Equipment & Supplies | $179.02B | 47x | -1.33 | $247.84 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.5% Upside | Upgrade to Pro+ | |
Pfizer | NYSE | Healthcare | Pharmaceuticals | $152.10B | 35.7x | -0.58 | $26.75 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.9% Upside | Upgrade to Pro+ | |
Boston Scientific | NYSE | Healthcare | Healthcare Equipment & Supplies | $150.89B | 84x | 1.78 | $102.32 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -1.3% Downside | Upgrade to Pro+ | |
Amgen | NASDAQ | Healthcare | Pharmaceuticals | $150.88B | 35.7x | -0.79 | $280.30 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.7% Upside | Upgrade to Pro+ | |
Stryker | NYSE | Healthcare | Healthcare Equipment & Supplies | $150.87B | 42.1x | 1.09 | $395.15 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4% Upside | Upgrade to Pro+ | |
Sanofi ADR | NASDAQ | Healthcare | Pharmaceuticals | $132.38B | 25.5x | -0.55 | $52.97 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.1% Upside | Upgrade to Pro+ | |
Essilor International SA | OTC Markets | Healthcare | Healthcare Equipment & Supplies | $123.37B | 51.1x | -14.48 | $135.40 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -10.6% Downside | Upgrade to Pro+ | |
Bristol-Myers Squibb | NYSE | Healthcare | Pharmaceuticals | $119.18B | -16.5x | 0.09 | $58.76 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.1% Upside | Upgrade to Pro+ | |
Medtronic | NYSE | Healthcare | Healthcare Equipment & Supplies | $118.10B | 28.1x | 4.47 | $91.98 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3.2% Upside | Upgrade to Pro+ | |
Gilead | NASDAQ | Healthcare | Pharmaceuticals | $117.24B | 935.5x | -9.4 | $93.85 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5% Upside | Upgrade to Pro+ | |
Vertex | NASDAQ | Healthcare | Biotechnology & Medical Research | $113.73B | -237.8x | 2.07 | $440.68 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.7% Upside | Upgrade to Pro+ | |
Elevance Health | NYSE | Healthcare | Healthcare Providers & Services | $94.05B | 15.8x | 8.6 | $405.40 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.7% Upside | Upgrade to Pro+ | |
Cigna | NYSE | Healthcare | Healthcare Providers & Services | $85.55B | 28.2x | -0.67 | $302.82 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.9% Upside | Upgrade to Pro+ | |
CSL | OTC Markets | Healthcare | Pharmaceuticals | $83.50B | 31.5x | 1.55 | $85.23 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.7% Upside | Upgrade to Pro+ | |
HCA | NYSE | Healthcare | Healthcare Providers & Services | $83.38B | 14.9x | 0.86 | $328.70 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.9% Upside | Upgrade to Pro+ |